ClinicalTrials.gg
Active, not recruitingNCT07226011Updated Sep 4, 2026

Accelerated High-Dose tDCS for Depression

An interventional study of Transcranial Direct Current Stimulation (tDCS) in Major Depression and Major Depression Disorders, sponsored by Medical University of South Carolina. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Depressive Disorder, Major by Medical University of South Carolina — 2 open to participants now, 4 under way, none of them phase 3. Depressive Disorder, Major · Medical University of South Carolina.

Planned enrollment
3rd of 11
20 · median 17
Started
2025
the only one that year
No phase
7 of 12
2 open now
Registered
11th of 12
by date

Among the 12 studies in Depressive Disorder, Major by Medical University of South Carolina, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 7 with no phase, and was the 11th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

2 of the 12 studies in Depressive Disorder, Major by Medical University of South Carolina are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Depressive Disorder, Major by Medical University of South Carolina, or all of them as a file.
02

Study summary

In this study, investigators are testing whether a higher dose of a non-invasive brain stimulation technique, called transcranial direct current stimulation (tDCS), can be safely used in people with depression. Participants will come to the Brain Stimulation Lab and receive mild electrical stimulation through electrodes placed on their scalp.

The study begins with a safety run-in, where the first few participants will receive stimulation at gradually increasing levels (2, 4, and 6 milliamps) while being closely monitored. If no serious side effects are found, later participants will receive repeated 6 milliamp sessions for 5 days total. Investigators will check skin comfort, mood, and overall tolerability after each session.

Read the detailed description

Major depressive disorder (MDD) remains one of the leading causes of disability worldwide, with many patients experiencing inadequate response to currently available treatments. Transcranial direct current stimulation (tDCS) has shown promise as a non-invasive, well-tolerated neuromodulation technique for depression, but nearly all prior studies have used lower current intensities (≤2 mA). Preliminary modeling and experimental work suggest that higher current dosing may be necessary to achieve sufficient engagement of cortical targets and produce stronger clinical effects.

The present study is designed to address this gap by systematically evaluating the safety, tolerability, and feasibility of high-dose tDCS delivered at 6 mA in adults with MDD. Establishing safety at this higher intensity is a critical step before pursuing larger efficacy trials. By carefully monitoring adverse events and skin integrity during an initial run-in phase, this study provides an evidence base for whether 6 mA tDCS can be safely implemented in a clinical population.

03

Conditions studied

  • Major Depression
  • Major Depression Disorders

Keywords

  • Depression
  • Nervous System
  • tDCS
  • Interventional
  • Brain Stimulation
  • Transcranial Direct Stimulation
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 18-70.
  • Current MDD diagnosis (MINI v7).
  • Baseline PHQ-9 > 9.
  • Capacity to consent
  • Fluent English.

Exclusion criteria

Exclusion Criteria:

  • Bipolar or psychotic disorder
  • Primary anxiety disorders without concomitant major depression as defined above
  • Current significant suicidal ideation or behaviors require a higher level of care.
  • Use of neuromodulation therapies (e.g., ECT, TMS, VNS) within the past 6 months.
  • History of seizures, implanted cranial/ cardiac metal, or neurosurgery.
  • Use of medications that significantly reduce seizure threshold
  • Frequent/severe HA
  • Personal history of head trauma, concussion, or TBI
  • Catatonic or otherwise unable to perform the consent process
  • Current alcohol or substance-use disorder (moderate-severe).
  • Any non-uniformities in the skin under the electrode site, including eczema, severe rashes, hyperhidrosis, communicable skin disorders, sensitive skin (ex. eczema, severe rashes), blisters, open wounds, burns including sunburns, cuts or irritation (e.g. due to shaving), or other skin defects or lesions, as determined by clinical personnel
  • Pregnancy (urine test required for women of ).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Experimental: High-Dose tDCS Intervention

    Participants in this single-arm, open-label pilot study will receive high-dose transcranial direct current stimulation (tDCS) for major depressive disorder. Each participant undergoes twice-daily 20-minute sessions at 6 mA for five consecutive weekdays (total of 10 sessions). The first three participants complete an in-lab dose-escalation safety run-in (2 mA → 4 mA → 6 mA on Day 1) with a Day 2 skin integrity check before continuing at 6 mA twice daily for the remaining days. All participants complete baseline, post-intervention, and 4-week follow-up assessments of depressive symptoms, cognition, and tolerability.

    Device: Transcranial Direct Current Stimulation (tDCS)

Interventions

  • DeviceTranscranial Direct Current Stimulation (tDCS)

    Participants receive transcranial direct current stimulation (tDCS) using a high-dose (6 mA) protocol delivered twice daily for five consecutive weekdays (10 sessions total). The first three participants complete a Day 1 in-lab dose-escalation (2 mA → 4 mA → 6 mA) with a Day 2 skin integrity check before continuing at 6 mA. All sessions last 20 minutes and are followed by adverse-event monitoring.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Device-Related Serious Adverse Events

    Defined as events requiring hospitalization or emergency care during the stimulation period.

    Time frame: Up to 7 days

  2. Number of Participants Completing All Scheduled Sessions Without Discontinuation

    Up to 5 days

    Time frame: Completion of all planned stimulation sessions without dropout due to adverse effects.

  3. Mean Score on Adverse Event Questionnaire

    Average Likert-scale ratings of discomfort, headache, or skin irritation.

    Time frame: Daily during treatment (Days 1-5)

Secondary outcomes

  1. Change in Depression Severity Score From Baseline to Post-Treatment

    Self-reported depression severity using a validated scale.

    Time frame: Baseline to Day 5

  2. Change in Cognitive Function Score From Baseline to Post-Treatment

    Subjective cognitive performance measured via standardized instrument.

    Time frame: Baseline to Day 5

  3. Change in Mindfulness Score From Baseline to Post-Treatment

    Self-reported mindfulness using a validated scale.

    Time frame: Baseline to Day 5

  4. Change in Depression Severity Score From Baseline to 4-Week Follow-Up

    Longitudinal assessment of symptom durability.

    Time frame: Baseline to 4 weeks post-treatment

  5. Electric Field Intensity in Target Brain Regions Based on MRI Modeling

    Retrospective modeling of intracerebral current flow using structural MRI.

    Time frame: Within 30 days of MRI scan

07

Study locations

1 site
  • MUSC Brain Stimulation Lab
    Charleston, South Carolina 29407, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 12 months is below that.

Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2025
First posted
Nov 10, 2025
StartActual
Dec 15, 2025
Primary completionEst.
Dec 28, 2026
CompletionEst.
Dec 30, 2026
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07226011
Responsible party
Mark George (Distinguished University Professor of Psychiatry, Radiology and Neuroscience, Medical University of South Carolina) — Principal investigator
First posted
Nov 10, 2025
Start date
Dec 15, 2025
Primary completion
Dec 28, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Sep 4, 2026

Study contacts

Clayton Olash, MD
study director · Medical University of South Carolina

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion